Early Detection Can Save Life and Prevent the Suffering and Cost of Treating Disease

  • Many cancers and other complex disease are detected late.
  • Late detection results in increased morbidity and death
  • Examples; liver, lung and gastric cancer
  • Current biomarkers lack sensitivity and specificity to detect disease early.
  • Available biomarkers and diagnostic methods are invasive; can’t be used for follow-up of healthy populations
  • Not applicable for follow up of large “healthy” populations that are at risk
Early detection of cancer HKG Epitherapeutics

Our Services

EPILIVER

Patent pending

Early detection of liver cancer

  • Detects conversion of patients with chronic hepatitis or healthy controls to early stage liver cancer HCC
  • Targets were clinically validated in studies in Yuan hospital in Beijing published in Clinical Epigenetics 2018. PCT world patent protection in national stage (US, Europe, Canada, Indonesia, India, Japan)
  • Next generation sequencing assay fully optimized clinically tested

EPIBREAST

Patent pending

Early detection of breast cancer

Coming soon…

epiCervix

Patent pending

Early detection of cervical cancer

Coming soon…

HKG EPITHERAPEUTICS STRATEGY

  • DNA methylation marks are an exquisite “ID” of a cell representing its past experiences and predicting its future.​
  • The exquisite profile of DNA methylation marks in white blood cells is mapped at the earliest stage of disease. Computational methods are used to reveal a combination of marks (polygenic) that can predict the earliest appearance of disease
  • Next generation sequencing methods are optimized to develop a high throughput robust assay for polygenic markers of disease.

DNA Methylation Polygenic Profiles Predicting HCC

Pin It on Pinterest

Scroll to Top